Young P C, Ehrlich C E, Einhorn L H
Cancer. 1980 Dec 15;46(12 Suppl):2961-3. doi: 10.1002/1097-0142(19801215)46:12+<2961::aid-cncr2820461444>3.0.co;2-e.
The relationship between steroid receptor content and response of metastatic breast cancers to endocrine therapy and cytotoxic chemotherapy has been examined. In 54 advanced breast cancers treated with hormonal therapy, 20 of 29 (69%) ER+, PR+ and 3 of 14 (21%) ER+, PR- tumors responded. Of the nine tumors that lacked both ER and PR, 2 (22%) were hormonally responsive. Based on either the ER or PR content alone, 68% of the PR+ and 54% of the ER+ tumors responded to endocrine therapy. Thus, the addition of PR assay could improve the accuracy of ER assay in selecting a hormonally responsive breast cancer. In 29 advanced breast cancers treated with cytotoxic drugs, the presence of ER and/or PR in the tumors seemed to favor an objective response to cytotoxic chemotherapy. The response rate was about 67% regardless of whether the cancers were ER+ or PR+.
已经研究了类固醇受体含量与转移性乳腺癌对内分泌治疗和细胞毒性化疗反应之间的关系。在接受激素治疗的54例晚期乳腺癌中,29例ER +、PR +肿瘤中有20例(69%)有反应,14例ER +、PR -肿瘤中有3例(21%)有反应。在9例既缺乏ER又缺乏PR的肿瘤中,2例(22%)对激素有反应。仅基于ER或PR含量,68%的PR +肿瘤和54%的ER +肿瘤对内分泌治疗有反应。因此,增加PR检测可以提高ER检测在选择激素反应性乳腺癌方面的准确性。在接受细胞毒性药物治疗的29例晚期乳腺癌中,肿瘤中ER和/或PR的存在似乎有利于对细胞毒性化疗产生客观反应。无论癌症是ER +还是PR +,反应率约为67%。